Vaccines Market - 2024-2032

September 2025 | 218 pages | ID: V3C6AF9DFA13EN
DataM Intelligence

Abstracts

The Vaccines Market was valued at US$ 77.01 billion in 2024 and is anticipated to reach US$ 108.82 billion by 2032, at a CAGR of 0.039 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Vaccines Market.

This report delivers a comprehensive overview of the Vaccines Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Vaccines Market. The Vaccines Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.

Vaccines Market Scope:

By Type

• Conjugate Vaccines
• Inactivated Vaccines
• Live-attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Viral Vector Vaccines
• Others

By Category

• Monovalent Vaccines
• Bivalent Vaccines
• Multivalent Vaccines

By Disease Indication

• Chickenpox
• Cholera
• Diphtheria
• Influenza
• Hepatitis
• Measles
• Mumps
• Polio
• Rabies
• Others

By Route of Administration

• Intramuscular
• Subcutaneous
• Intranasal
• Others

By End User

• Community Hospitals
• Hospitals
• Specialty Centers
• Clinics
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Key Players

• Pfizer Inc.
• Amgen Inc.
• Johnson & Johnson Services, Inc.
• F. Hoffmann-La Roche Ltd
• Dr. Reddy’s Laboratories Ltd.
• Intas Pharmaceuticals
• Akron Biotech
• Sandoz Group AG
• ratiopharm GmbH
• Biocon Limited

Major Highlights

This report delivers a comprehensive overview of the Vaccines Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Vaccines Market. The Vaccines Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Type
3.2. Snippet by Category
3.3. Snippet by Disease Indication
3.4. Snippet by Route of Administration
3.5. Snippet by End User
3.6. Snippet by Distribution Channel
3.7. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Rising development of vaccines
  4.1.2. Restraints
    4.1.2.1. Competition from alternative treatments
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. BY TYPE

6.1. Introduction
  6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  6.1.2. Market Attractiveness Index, By Type
6.2. Conjugate Vaccines*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Inactivated Vaccines
6.4. Live-attenuated Vaccines
6.5. Recombinant Vaccines
6.6. Toxoid Vaccines
6.7. Viral Vector Vaccines
6.8. Others

7. BY CATEGORY

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  7.1.2. Market Attractiveness Index, By Drug Type
7.2. Monovalent Vaccines*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bivalent Vaccines
7.4. Multivalent Vaccines

8. BY DISEASE INDICATION

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  8.1.2. Market Attractiveness Index, By Disease Indication
8.2. Chickenpox*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cholera
8.4. Diphtheria
8.5. Influenza
8.6. Hepatitis
8.7. Measles
8.8. Mumps
8.9. Polio
8.10. Rabies
8.11. Others

9. BY ROUTE OF ADMINISTRATION

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Intramuscular*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Subcutaneous
9.4. Intranasal
9.5. Others

10. BY END USER

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  10.1.2. Market Attractiveness Index, By End User
10.2. Community Hospitals*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hospitals
10.4. Specialty Centers
10.5. Clinics
10.6. Others

11. BY DISTRIBUTION CHANNEL

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacy*
  11.2.1. Introduction
  11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacy
11.4. Online Pharmacy

12. BY REGION

12.1. Introduction
  12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  12.1.2. Market Attractiveness Index, By Region
12.2. North America
  12.2.1. Introduction
  12.2.2. Key Region-Specific Dynamics
  12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  12.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    12.2.9.1. U.S.
    12.2.9.2. Canada
    12.2.9.3. Mexico
12.3. Europe
  12.3.1. Introduction
  12.3.2. Key Region-Specific Dynamics
  12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  12.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    12.3.9.1. Germany
    12.3.9.2. U.K.
    12.3.9.3. France
    12.3.9.4. Spain
    12.3.9.5. Italy
    12.3.9.6. Rest of Europe
12.4. South America
  12.4.1. Introduction
  12.4.2. Key Region-Specific Dynamics
  12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  12.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    12.4.9.1. Brazil
    12.4.9.2. Argentina
    12.4.9.3. Rest of South America
12.5. Asia-Pacific
  12.5.1. Introduction
  12.5.2. Key Region-Specific Dynamics
  12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  12.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    12.5.9.1. China
    12.5.9.2. India
    12.5.9.3. Japan
    12.5.9.4. South Korea
    12.5.9.5. Rest of Asia-Pacific
12.6. Middle East and Africa
  12.6.1. Introduction
  12.6.2. Key Region-Specific Dynamics
  12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Category
  12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  12.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. COMPETITIVE LANDSCAPE

13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis

14. COMPANY PROFILES

14.1. Pfizer Inc.*
  14.1.1. Company Overview
  14.1.2. Product Portfolio and Description
  14.1.3. Financial Overview
  14.1.4. Key Developments
14.2. Amgen Inc.
14.3. Johnson & Johnson Services, Inc.
14.4. F. Hoffmann-La Roche Ltd
14.5. Dr. Reddy’s Laboratories Ltd.
14.6. Intas Pharmaceuticals
14.7. Akron Biotech
14.8. Sandoz Group AG
14.9. ratiopharm GmbH
14.10. Biocon Limited (*LIST NOT EXHAUSTIVE)

15. APPENDIX

15.1. About Us and Services
15.2. Contact Us